The ERC Proof of Concept grant offers 150,000 euros to fund the development of new drugs against fibrosis within 18 months.
The SENFIB project aims to eliminate senescent cells. These are damaged cells which, if not destroyed by the immune system, can give rise to aging-related diseases such as idiopathic pulmonary fibrosis and chronic kidney disease.
To achieve this aim, the project makes use of senolytics, molecules which lead to the selective death of these cells and have produced positive results in animal models.
The team led by Manuel Serrano, ICREA researcher and Head of the Cellular Plasticity and Disease Lab at IRB Barcelona, has been awarded the Proof of Concept grant by the European Research Council (ERC). This grant, created to support ideas that could benefit society, will provide the IRB Barcelona team with 150,000 euros to develop the SENFIB project over the next 18 months.
The goal of this project is to develop new medication for the treatment of fibrotic diseases such as idiopathic pulmonary fibrosis and chronic kidney disease. To do this, the research project aims to target senescent cells. These are cells which have permanently exited the cell cycle after suffering damage or stress, and cause persistent inflammation which can give rise to ageing-related diseases.
In animal models, the selective elimination of senescent cells has proven to have therapeutic effects on idiopathic pulmonary fibrosis, chronic kidney disease and ageing. Manuel Serrano’s laboratory, which also has the backing of the "La Caixa" Foundation, is proposing to launch a programme to discover senolytics, molecules which cause the preferential death of senescent cells whilst leaving the healthy cells intact.
As Manuel Serrano explains: “senescent cells are damaged cells which remain in the organism and lead to the functional deterioration of tissue and organs. Senolytics allow us to selectively eliminate these cells when the immune system is unable to do so, thus preventing the appearance of ageing-related diseases”.
In fact, senolytics have become a promising focal point to combat ageing-related diseases, and the MIT recently mentioned them as one of the "Top 10 breakthrough technologies" for 2020 in the MIT Technology Review.
The project could have a considerable impact, as it is calculated that a fourth of the global population will be over the age of 65 by 2050 and will therefore be more likely to suffer from degenerative diseases such as fibrosis, which cause up to 45% of deaths in this segment of the population.
The new senolytics will be aimed at targets previously discovered by Marta Kovatcheva, a postdoctoral researcher and member of the research team. As Marta explains, “It is a very interesting example of how basic research can open the doors to clinical translation. The ERC’s Proof of Concept project allows us to make the leap and engage with the concerns of society.”
About IRB Barcelona
Created in 2005 by the Generalitat de Catalunya (Government of Catalonia) and University of Barcelona, IRB Barcelona is a Severo Ochoa Centre of Excellence, a seal that was awarded in 2011. The institute is devoted to conducting research of excellence in biomedicine and to transferring results to clinical practice, thus improving people’s quality of life, while simultaneously promoting the training of outstanding researchers, technology transfer, and public communication of science. Its 28 laboratories and eight core facilities address basic questions in biology and are orientated to diseases such as cancer, metastasis, Alzheimer’s, diabetes, and rare conditions. IRB Barcelona is an international centre that hosts 400 employees and more than 30 nationalities. It is located in the Barcelona Science Park. IRB Barcelona is a CERCA center, and a member of the Barcelona Institute of Science and Technology (BIST).